SAB Biotherapeutics, Inc.
SABS
$3.94
-$0.21-5.06%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 6,469.22% | 107.02% | |||
| Gross Profit | -6,469.22% | -107.02% | |||
| SG&A Expenses | 62.90% | 35.59% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 24.38% | 30.28% | |||
| Operating Income | -24.38% | -30.28% | |||
| Income Before Tax | -137.10% | 549.32% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -137.10% | 549.32% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -137.10% | 549.32% | |||
| EBIT | -24.38% | -30.28% | |||
| EBITDA | -25.97% | -33.00% | |||
| EPS Basic | -111.84% | -33.16% | |||
| Normalized Basic EPS | -108.24% | 491.94% | |||
| EPS Diluted | -17.92% | -128.38% | |||
| Normalized Diluted EPS | -160.20% | 153.66% | |||
| Average Basic Shares Outstanding | 350.22% | 14.64% | |||
| Average Diluted Shares Outstanding | -38.36% | 737.28% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||